BFRI

2.21% -0.0221

アフターアワーズ： .97 -0.0079 -0.81%

Biofrontera Inc (BFRI)

概要ニュース株価時系列 Financials ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1181)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

BFRI's Discussions on Twitter

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera Inc (BFRI) 財務データ

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Biofrontera Inc. Announces Highly Significant Results In - GlobeNewswire

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Mass. Biotech Receives FDA Approval - Streetwise Reports

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance

Five PDUFA dates on FDA’s October agenda - BioCentury

Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech

Biotech Stocks Facing FDA Decision In October 2024 - Nasdaq

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan

Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News

Trading Day Triumph: Biofrontera Inc (BFRI) Ends at 1.28, a 0.00 Surge/Plunge - The Dwinnex

A stock that deserves closer examination: Biofrontera Inc (BFRI) - US Post News

Leidos Holdings, Inc. (NYSE:LDOS) Shares Sold by Tredje AP fonden - Defense World

Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex

Taking the lead: Biofrontera Inc (BFRI) - SETE News

Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle

Biofrontera Inc (BFRI) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Biofrontera Inc (BFRI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle

Biofrontera Inc (BFRI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Biofrontera Inc (BFRI)’s results reveal risk - US Post News

Louisiana State Employees Retirement System Acquires 700 Shares of HNI Co. (NYSE:HNI) - Defense World

A SPAC II Acquisition Corp. (NASDAQ:ASCB) Sees Large Decrease in Short Interest - Defense World

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Biofrontera (NASDAQ:BFRI) Stock Rating Reaffirmed by Benchmark - Defense World

Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Biofrontera Inc (BFRI) 財務データ

収益

当期純利益

現金流量

EPS

BFRIに似た銘柄